TP53 and cancer: Although there are no FDA-approved drugs targeting p53 (wild-type or mutant), advanced strategies based on p53 structure and function have continued to be developed for targeting p53 in cancer therapy (Figure 2 and Figure 3), and some of them are under clinical evaluation (Table 1).